Determination of doxorubicin in blood plasma based on quantum dots fluorescence quenching process
Koganova D.G., Meshcheriakova S.A., Goryacheva O.A., Goryacheva I.Yu.;
Saratov State University, Saratov, Russia;
Abstract
Doxorubicin (Dox) is an effective drug from the group of anthracycline antibiotics, which has high activity against many types of cancer and is widely used in chemotherapy. It has high cardiotoxicity, as well as cyto- and neurotoxicity. For this reason, it is necessary to constantly monitor the concentration of Dox in the body.
Several methods are known for monitoring Dox concentrations in tissues and biofluids, but they are complex and costly. These include high-performance liquid chromatography, voltammetry, and others. Doxorubicin has intrinsic fluorescence intensity in the range of 540-660 nm. However, the fluorescence intensity is too low to detect it at low concentrations in the blood. At the same time, the absorption spectra of Dox overlap with the fluorescence spectra of quantum dots (QDs). These two factors allow the use of QDs as a detector of Dox. The fluorescence of QDs in the presence of DOX molecules decreases, which may be the result of nonradiative energy transfer.
This study showed that when Dox is detected in blood plasma using a nanosensor based on fluorescence quenching. The fluorescence intensity of QDs decreases with increasing Dox concentration, compared to aqueous solution. This method demonstrates the feasibility of determining Dox in human blood.
Speaker
Koganova Darya G.
Saratov State University, Saratov, Russia
Russia
Discussion
Ask question
